Innovative Oncology Network

A platform to improve oncology care by disseminating knowledge and innovative approaches to education and patient care.

[JIPO Editors @JIPOEditors]

Brand new call for papers with #JIPO: Submit your work related to AI in Immunotherapy, Precision Oncology, & Clinical Trials: https://t.co/I5b7MMlnsm #aiimmunotherapy #aioncology #aihealthcare @InnoJournals @OncologyNetwork

[JIPO Editors @JIPOEditors]

Limaye et al. report on a case which challenges the conventional paradigm that EGFR-mutated NSCLC does not benefit from immunotherapy https://t.co/I7DRayXPFX #immunotherapy #precisiononcology @OncologyNetwork

[OncoAlert @OncoAlert]

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

✅ LBA6 — Phase 3 trial of [¹⁷⁷Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAaddition)

✅LBA86 — Randomised phase 3 trial of ADT with radiation therapy with or without enzalutamide for high-risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

✅2383O — Capivasertib + abiraterone vs placebo + abiraterone in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281

✅LBA87 — EMBARK: OS with enzalutamide in biochemically recurrent prostate cancer

✅LBA93 — RAMPART: Adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma

✅2591O — Efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker

✅LBA2 — Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905

✅LBA7 — Disitamab vedotin plus toripalimab vs chemotherapy in first-line locally advanced or metastatic urothelial carcinoma with HER2-expression

✅LBA8 — IMvigor011: A phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer

✅LBA109 — DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer

✅LBA111 — Randomized comparison of upfront MRI versus transurethral resection for staging new bladder cancers: final survival analysis from the BladderPath trial

✅LBA37 — Avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemo (ALPACA)

Senior Faculty
🇨🇭 Dr. Gillessen
🇺🇸Dr. Agarwal
🇺🇸Dr. Zhang
🇺🇸Dr. Rini
🇺🇸Dr. Grivas
🇬🇧 Dr. Chowdhury

AF Collaborators
🇧🇷 Dr. Melao
🇮🇳 Dr. Jain

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @ReginaBarCar

[JIPO Editors @JIPOEditors]

Watson et al. review the combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas, in #JIPO review article https://t.co/EgzkX48Nf6 #sarcoma #targetedtherapies @DoubaZain @ANaingMD @OncologyNetwork

[Dr Rishabh Jain @DrRishabhOnco]

2024 wasn’t evolution in bladder cancer - it was a revolution 🔄💥

Top breakthroughs 👇

💊 TAR-200 (intravesical gemcitabine device) → CR 82% in BCG-unresponsive NMIBC (SunRISe-1)

🛡️ Adjuvant ICI →

•Nivolumab DFS HR 0.70; OS HR 0.76 (CheckMate-274)

•Pembrolizumab DFS 29.6 vs 14.2 mo, HR 0.73 (AMBASSADOR)

🧬 ctDNA → biomarker to guide adjuvant ICI (IMvigor011, TOMBOLA)

💉 Durva + Gem/Cis → first periop chemo-IO with OS benefit in MIBC (NIAGARA), EFS HR 0.68; OS HR 0.75

💎 EV + Pembro → OS 31.5 vs 16.1 mo, ORR 68% in 1L mUC (EV-302)

⚖️ New standards across the spectrum → NMIBC ➝ MIBC ➝ mUC

📖 Full paper in comment ⬇️

#BladderCancer #UroOnc #OncoTwitter
@OncoAlert @oncodaily @ASCO @myESMO

[Annals of Oncology @Annals_Oncology]

🆕article in press: Randomized, double-blind, phase III LEAP-003 Study of first-line lenvatinib plus pembrolizumab vs. placebo plus pembrolizumab for unresectable or metastatic melanoma @ProfGLongMIA
https://t.co/9ednRi00H6

[Innovative Oncology Network @OncologyNetwork]

Follow Innovative Oncology Network on various social media platforms and help disseminate relevant and timely knowledge

WhatsApp Community
https://t.co/p6g16b5Z2o

LinkedIn

https://t.co/e4GaHovK7P

Facebook

https://t.co/ytvdbCgj0b

X Platform

https://t.co/esbXDgBsH3

[Innovative Oncology Network @OncologyNetwork]

Consider submitting articles in this important topic
#CancerResearch
#oncology

[JIPO Editors @JIPOEditors]

#JIPO invites manuscript submissions highlighting regional advances and challenges in #precisiononcology. Submit your paper by September 1, 2025. https://t.co/pqVGcLht7z @InnoJournals @OncologyNetwork

[Innovative Oncology Network @OncologyNetwork]

Congratulations to #JIPO team
#Oncology #Immunology #CancerResearch #publication

[JIPO Editors @JIPOEditors]

Did you hear the news? #JIPO has received its 1st official #impactfactor = 3.2!

Read some of our newest articles https://t.co/OVuur2Rbjr

[Innovative Oncology Network @OncologyNetwork]

#alcohol #cancer #CancerResearch #CancerPrevention

[JAMA @JAMA_current]

Any daily #alcohol consumption is associated with certain cancers, and the risk of #cancer increases with higher alcohol intake.

📊 This JAMA Insights discusses the evidence related to the @Surgeon_General’s Advisory on alcohol and cancer risk.

https://t.co/7iNaQIWYOb

[Nature Cancer @NatureCancer]

👇Check out new Review article @NatureCancer on cancer nanotechnology by Betty Kim and colleagues
https://t.co/n0btxzo1KL

[ASCO @ASCO]

It's time to register! Join our commitment to advancing the quality, safety, and efficiency of cancer care delivery. Find support, inspiration, and meaningful discussion among a network of peers at ASCO Quality Care Symposium.

[OncoAlert @OncoAlert]

The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week August 8-14, 2025

👉REGISTER at https://t.co/QFM2SYXqbg OR https://t.co/hwvqbilbLO

Discussing:
✅Extending the duration of ET for early #BreastCancer

✅Nemvaleukin alfa monoTX in advanced #Melanoma

✅Discovery of BMS-986365, in #ProstateCancer

✅Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative #BreastCancer

✅ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or #immunotherapy

✅Real-world evidence of chemotherapy effects in advanced #PancreaticCancer

✅Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS🧬targeted therapy in gastrointestinal cancers

✅Enhanced Detection of Druggable Mutations in #NSCLC Using Bronchial Washing Fluid🫁

and much more

@drenriquegrande
@tompowles1
@DrChoueiri
@bergsa83
@SuyogCancer
@Ian_Wendt_
@dralvaropinto
@DrYukselUrun
@UroDocAsh
@MattGalsky
@AnisToumeh
@drsarahsam
@DrHBurstein
@LiangRhea
@jamecancerdoc
@ChadTangMD
@NoraSundahl
@_ShankarSiva
@StephenVLiu
@medicalwatchBC
@aminfield
@drdsaydan
@benitezja
@bmassutis
@OcathailS

@matteolambe @Icro_Meattini @ARosen380 @JaniceTNBCmets @stolaney1

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

[JIPO Editors @JIPOEditors]

#JIPO commentary by Shroff and Brar discuss the use of Anti-PD-1 therapy for advanced #cholangiocarcinoma and its impacts https://t.co/dY8FLAUNzO #precisiononcology @ANaingMD

[JIPO Editors @JIPOEditors]

#CallforAbstracts: The #IPOF2025 Scientific Committee is seeking studies of artificial intelligence use in precision medicine.
Submit an abstract at https://t.co/Ah8WhBmS91

@OncologyNetwork @InnoJournals @Innovativehci #oncology #IPOF #AI #artificialintelligence

[JIPO Editors @JIPOEditors]

Review the current treatment options for Granulosa cell tumor #GCT including the role of novel therapies and immune checkpoint inhibitors https://t.co/iZAfcProcf by Salkeni et al. #JIPO #granulosacelltumors #rarecancers #FOXL2 @OncologyNetwork

[JIPO Editors @JIPOEditors]

November marks #NationalStomachCancerAwarenessMonth. Let’s work together to enhance awareness & improve outcomes for those affected by stomach cancer. @OncologyNetwork https://t.co/lGpMmUgO3j

[JIPO Editors @JIPOEditors]

Sheshadri et al. discuss the incidence, timing of onset, & imaging patterns of pneumonitis, specifically in relation to newly approved precision oncologic agents https://t.co/LNRyXqYhMO #JIPO #pneumonitis #precisiononcology @ajaysheshadri @sfaiz212 @mehmetaltanmd @OncologyNetwork

[JIPO Editors @JIPOEditors]

Learn the importance of multidisciplinary workup and management of respiratory symptoms and insufficiency in this case study about a patient w renal cell carcinoma by Faiz et al. @ajaysheshadri https://t.co/1IEeYdhUWf #immunotherapy #ICIs #JIPO @OncologyNetwork

[JIPO Editors @JIPOEditors]

Review recent #JIPO case study by Fox et al. "Durable remission after targeted therapy in BRAF V600E-mutant metastatic colorectal cancer" https://t.co/ikez7Jhs19 #vemurafenib #colorectalcancer #dMMR @OncologyNetwork